Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Tara Giuliano, Chief Marketing Officer, Nuveen Institutional Investor As Fundraising Stalls, Independent Sponsors Fill Gap in Lower-Middle Market James Comtois The Infrastructure Behind the AI Era: Why Data Centers Are Becoming a Critical Investment Opportunity Sponsored by Principal Asset Management